Germany's pharmaceutical industry warns against healthcare reform spending cuts

Germany's pharmaceutical industry has clashed with the government's healthcare reform plans, which would impose mandatory price reductions on manufacturers. Heidrun Irschik-Hadjieff, CEO of Sanofi Germany, warns that the proposed dynamic manufacturer discount could seriously damage investments.

A sharp dispute over healthcare reform has erupted in Germany, with the central question being whether the country can simultaneously remain a world-leading pharmaceutical manufacturing hub and implement cost-saving changes to its healthcare system.

Heidrun Irschik-Hadjieff, CEO of Sanofi Germany, has launched sharp criticism of the proposed dynamic manufacturer discount, which forms part of a broader reform of statutory health insurance financing. "This approach puts future investments in Germany at risk," she warned in a conversation with POLITICO healthcare expert Marie Zahout.

Manufacturer discount as the key point of contention

According to Irschik-Hadjieff, healthcare system savings and economic growth cannot be set in opposition to each other; they must ultimately be considered together. She emphasized that the current reform trajectory endangers Germany's competitiveness in the pharmaceutical sector globally and could drive away crucial investments.

The reform is based on the need to ensure sustainable financing of statutory health insurance, but pharmaceutical manufacturers argue that mandatory additional discounts place the burden disproportionately on a single sector.

Digital sovereignty in Europe

The same week, POLITICO Deutschland's "Power & Policy" show also addressed technology issues. Jasper Bennink brought German Digital Minister Karsten Wildberger to the Paris technology conference VivaTech, where discussion turned to a new German-French definition of digital sovereignty. The debate raised the question of whether Europe is even capable of operating independently and autonomously in the technology sector.